Novartis Drug PrJakaviA Associated with Significant Clinical Benefit for Patients with Debilitating and Life-threatening Blood Cancer Myelofibrosis DORVAL, QC , March 7, 2014 /CNW/ - Study results presented at the 55th American Society of Hematology annual meeting showed that patients with myelofibrosis who received treatment with JakaviA sustained ... (more)
http://ift.tt/P8Ktx3
http://ift.tt/P8Ktx3
No comments:
Post a Comment